Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations.
Lotte WesterinkJelmer L J NicolaiCarl SamuelsenHans J M SmitPieter E PostmusIngolf GriebschMaarten J PostmaPublished in: The European journal of health economics : HEPAC : health economics in prevention and care (2020)
First-line afatinib treatment in patients with EGFR-mutant NSCLC had a lower financial impact on the Dutch healthcare budget with a higher mean ToT and QALM compared to osimertinib sequential treatment.